Literature DB >> 28533135

Enhanced Local Disorder in a Clinically Elusive von Willebrand Factor Provokes High-Affinity Platelet Clumping.

Alexander Tischer1, Venkata R Machha1, Juan P Frontroth2, Maria A Brehm3, Tobias Obser3, Reinhard Schneppenheim4, Leland Mayne5, S Walter Englander6, Matthew Auton7.   

Abstract

Mutation of the cysteines forming the disulfide loop of the platelet GPIbα adhesive A1 domain of von Willebrand factor (VWF) causes quantitative VWF deficiencies in the blood and von Willebrand disease. We report two cases of transient severe thrombocytopenia induced by DDAVP treatment. Cys1272Trp and Cys1458Tyr mutations identified by genetic sequencing implicate an abnormal gain-of-function phenotype, evidenced by thrombocytopenia, which quickly relapses back to normal platelet counts and deficient plasma VWF. Using surface plasmon resonance, analytical rheology, and hydrogen-deuterium exchange mass spectrometry (HXMS), we decipher mechanisms of A1-GPIbα-mediated platelet adhesion and resolve dynamic secondary structure elements that regulate the binding pathway. Constrained by the disulfide, conformational selection between weak and tight binding states of A1 takes precedence and drives normal platelet adhesion to VWF. Less restrained through mutation, loss of the disulfide preferentially diverts binding through an induced-fit disease pathway enabling high-affinity GPIbα binding and firm platelet adhesion to a partially disordered A1 domain. HXMS reveals a dynamic asymmetry of flexible and ordered regions common to both variants, indicating that the partially disordered A1 lacking the disulfide retains native-like structural dynamics. Both binding mechanisms share common structural and thermodynamic properties, but the enhanced local disorder in the disease state perpetuates high-affinity platelet agglutination, characteristic of type 2B VWD, upon DDAVP-stimulated secretion of VWF leading to transient thrombocytopenia and a subsequent deficiency of plasma VWF, characteristic of type 2A VWD.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GPIbα; Von Willebrand disease; Von Willebrand factor; hydrogen–deuterium exchange mass spectrometry

Mesh:

Substances:

Year:  2017        PMID: 28533135      PMCID: PMC5839150          DOI: 10.1016/j.jmb.2017.05.013

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  50 in total

1.  Simulations of flow induced structural transition of the β-switch region of glycoprotein Ibα.

Authors:  Mengzhi Han; Ji Xu; Ying Ren; Jinghai Li
Journal:  Biophys Chem       Date:  2015-12-02       Impact factor: 2.352

2.  Force-induced on-rate switching and modulation by mutations in gain-of-function von Willebrand diseases.

Authors:  Jongseong Kim; Nathan E Hudson; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-25       Impact factor: 11.205

3.  Protein hydrogen exchange at residue resolution by proteolytic fragmentation mass spectrometry analysis.

Authors:  Zhong-Yuan Kan; Benjamin T Walters; Leland Mayne; S Walter Englander
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

Review 4.  A molecular approach to the classification of von Willebrand disease.

Authors:  R Schneppenheim; U Budde; Z M Ruggeri
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

5.  Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha.

Authors:  S Miyata; S Goto; A B Federici; J Ware; Z M Ruggeri
Journal:  J Biol Chem       Date:  1996-04-12       Impact factor: 5.157

6.  Characterization of recombinant von Willebrand factors mutated on cysteine 509 or 695.

Authors:  V Siguret; A S Ribba; O Christophe; G Chérel; B Obert; C Rouault; T Nishikubo; D Meyer; J P Girma; G Piétu
Journal:  Thromb Haemost       Date:  1996-09       Impact factor: 5.249

7.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

8.  C1272F: a novel type 2A von Willebrand's disease mutation in A1 domain; its clinical significance.

Authors:  A I Woods; A Sanchez-Luceros; A C Kempfer; Y Powazniak; J C Calderazzo Pereyra; A N Blanco; S S Meschengieser; M A Lazzari
Journal:  Haemophilia       Date:  2011-05-18       Impact factor: 4.287

9.  A molten globule intermediate of the von Willebrand factor A1 domain firmly tethers platelets under shear flow.

Authors:  Alexander Tischer; Pranathi Madde; Luis M Blancas-Mejia; Matthew Auton
Journal:  Proteins       Date:  2013-11-22

10.  Defects in type IIA von Willebrand disease: a cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib-IX.

Authors:  J M Lavergne; L De Paillette; B R Bahnak; A S Ribba; E Fressinaud; D Meyer; G Pietu
Journal:  Br J Haematol       Date:  1992-09       Impact factor: 6.998

View more
  6 in total

1.  Glycosylation sterically inhibits platelet adhesion to von Willebrand factor without altering intrinsic conformational dynamics.

Authors:  Alexander Tischer; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Matthew Auton
Journal:  J Thromb Haemost       Date:  2019-09-03       Impact factor: 5.824

2.  ThANNCs for kinetically optimizing ITC.

Authors:  Matthew Auton
Journal:  Biophys J       Date:  2022-05-25       Impact factor: 3.699

3.  Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.

Authors:  Klaus Bonazza; Roxana E Iacob; Nathan E Hudson; Jing Li; Chafen Lu; John R Engen; Timothy A Springer
Journal:  Elife       Date:  2022-05-09       Impact factor: 8.713

4.  Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.

Authors:  Alexander Tischer; Maria A Brehm; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Katelynn J Nelton; Rachel R Leger; Tobias Obser; Marina Martinez-Vargas; Steven T Whitten; Dong Chen; Rajiv K Pruthi; H Robert Bergen; Miguel A Cruz; Reinhard Schneppenheim; Matthew Auton
Journal:  J Mol Biol       Date:  2019-10-17       Impact factor: 5.469

5.  A p.Arg127Gln variant in GPIbα LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD.

Authors:  Loredana Bury; Emanuela Falcinelli; Haripriya Kuchi Bhotla; Anna Maria Mezzasoma; Giuseppe Guglielmini; Alexander Tischer; Laurie Moon-Tasson; Matthew Auton; Paolo Gresele
Journal:  Blood Adv       Date:  2022-04-12

6.  The Chaperonin GroEL: A Versatile Tool for Applied Biotechnology Platforms.

Authors:  Pierce T O'Neil; Alexandra J Machen; Benjamin C Deatherage; Caleb Trecazzi; Alexander Tischer; Venkata R Machha; Matthew T Auton; Michael R Baldwin; Tommi A White; Mark T Fisher
Journal:  Front Mol Biosci       Date:  2018-05-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.